SNB-101 is under clinical development by SN BioScience and currently in Phase I for Rectal Cancer. According to GlobalData, Phase I drugs for Rectal Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the SNB-101 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SNB-101 overview
SNB-101 is under development for the treatment of pancreatic, ovarian, gastric, colorectal, breast, head and neck, rectal cancer, non-small cell lung cancer, biliary tract cancer and small cell lung cancer. The drug candidate is administered through intravenous and intratumor route. It comprises of SN-38 glucuronide as active ingredient. SN-38 glucuronide is a metabolite of irinotecan. It acts by targeting topoisomerase I. The drug candidate is developed based on Double Core-Shell Micelle and Micelle-Liposome Hybrid Cell technology.
It was also under development for the treatment of prostate cancer.
SN BioScience overview
SN BioScience is a research and development of drug delivery technology such as liposome, micelle and nanoparticle in the pharmaceutical sector and led the commercialize anticancer and metabolic disease drugs. The company is headquartered in Seongnam, South Korea.
For a complete picture of SNB-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.